Please login to the form below
Natpar
This page shows the latest Natpar news and features for those working in and with pharma, biotech and healthcare.
Shire finally bags EU approval for rare disease drug Natpar
Becomes first licenced treatment for hypoparathyroidism in Europe. Shire is celebrating an EU approval for its hypoparathyroidism treatment Natpar, two years after getting a green light for the drug in the ... US. Natpar - which is sold as Natpara in the
Latest news
-
Relief for Shire as FDA clears NPS' Natpara
If approved, the drug will be sold in the EU as Natpar.
-
Shire signs deal to buy NPS for $5.2bn
The drug could benefit from Shire's marketing muscle on both sides of the Atlantic, said Ornskov, and could soon be joined by Natpara/Natpar (recombinant parathyroid hormone) for the treatment
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Keytruda doubles five-year survival rate in NSCLC
- 3 ways to increase patient retention rates in clinical trials
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- 3 ways to increase patient retention rates in clinical trials
- Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
Quick links
Infographics
